Actelion Ltd - Product Pipeline Review - 2015

Published: Apr, 2015 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Actelion Ltd - Product Pipeline Review - 2015

Summary 

Global Markets Direct's, 'Actelion Ltd - Product Pipeline Review - 2015', provides an overview of the Actelion Ltd's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Actelion Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Actelion Ltd including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Actelion Ltd's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Actelion Ltd's pipeline products

Reason To Buy 

- Evaluate Actelion Ltd's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Actelion Ltd in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Actelion Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Actelion Ltd and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Actelion Ltd
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Actelion Ltd and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Actelion Ltd Snapshot 6
Actelion Ltd Overview 6
Key Information 6
Key Facts 6
Actelion Ltd - Research and Development Overview 7
Key Therapeutic Areas 7
Actelion Ltd - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Actelion Ltd - Pipeline Products Glance 14
Actelion Ltd - Late Stage Pipeline Products 14
Pre-Registration Products/Combination Treatment Modalities 14
Phase III Products/Combination Treatment Modalities 15
Actelion Ltd - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Actelion Ltd - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Actelion Ltd - Drug Profiles 20
selexipag 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
cadazolid 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
macitentan 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ponesimod 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
miglustat 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule to Agonize S1P1 Receptor for Systemic Lupus Erythematosus 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ACT-246475 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ACT-281959 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ACT-389949 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ACT-451840 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ACT-462206 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
lucerastat 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecule for Cardiovascular Disorders 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecule for Neurological Disorders 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecule to Inhibit DNA Gyrase and Topoisomerase IV for Bacterial Infection 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules to Inhibit DNA Ligase for Staphylococcal Infections 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecule for Cancer 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Actelion Ltd - Pipeline Analysis 41
Actelion Ltd - Pipeline Products by Target 41
Actelion Ltd - Pipeline Products by Route of Administration 42
Actelion Ltd - Pipeline Products by Molecule Type 43
Actelion Ltd - Pipeline Products by Mechanism of Action 44
Actelion Ltd - Recent Pipeline Updates 45
Actelion Ltd - Dormant Projects 51
Actelion Ltd - Discontinued Pipeline Products 52
Discontinued Pipeline Product Profiles 52
almorexant 52
clazosentan 52
palosuran 52
Actelion Ltd - Company Statement 53
Actelion Ltd - Locations And Subsidiaries 54
Head Office 54
Other Locations & Subsidiaries 54
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables

Actelion Ltd, Key Information 6
Actelion Ltd, Key Facts 6
Actelion Ltd - Pipeline by Indication, 2015 9
Actelion Ltd - Pipeline by Stage of Development, 2015 10
Actelion Ltd - Monotherapy Products in Pipeline, 2015 11
Actelion Ltd - Partnered Products in Pipeline, 2015 12
Actelion Ltd - Partnered Products/ Combination Treatment Modalities, 2015 13
Actelion Ltd - Pre-Registration, 2015 14
Actelion Ltd - Phase III, 2015 15
Actelion Ltd - Phase II, 2015 16
Actelion Ltd - Phase I, 2015 17
Actelion Ltd - Preclinical, 2015 18
Actelion Ltd - Discovery, 2015 19
Actelion Ltd - Pipeline by Target, 2015 41
Actelion Ltd - Pipeline by Route of Administration, 2015 42
Actelion Ltd - Pipeline by Molecule Type, 2015 43
Actelion Ltd - Pipeline Products by Mechanism of Action, 2015 44
Actelion Ltd - Recent Pipeline Updates, 2015 45
Actelion Ltd - Dormant Developmental Projects,2015 51
Actelion Ltd - Discontinued Pipeline Products, 2015 52
Actelion Ltd, Subsidiaries 54